期刊文献+

7.0T心脏MR成像在肺动脉高压大鼠模型右心功能评估中的作用 被引量:1

Right ventricular function evaluation by 7.0T cardiac MRI in a rat model of pulmonary artery hypertension
下载PDF
导出
摘要 目的:基于7.0T心脏磁共振成像(cardiac magnetic resonance,CMR)观察肺动脉高压(pulmonary artery hypertension,PAH)大鼠肺动脉径线和心脏功能的变化。方法:选用36只雄性SD大鼠(随机分为6组,每组6只)采用低氧建立PAH大鼠模型。于未缺氧时(基线)及缺氧后第1、2、3、4、5周利用MR(Bruker BioSpec 7.0T)进行心脏成像,分别测量主肺动脉(main pulmonary artery,MPA)、右肺动脉(right pulmonary artery,RPA)、左肺动脉(left pulmonary artery,LPA)直径,并计算其与同层面升主动脉(ascending aorta,AA)直径之比(MPA/AA、RPA/AA、LPA/AA);四腔心位右室舒张末期最大径线(right ventricular end-diastolic maximum diameter,dRVmax)与左室舒张末期最大径线(left ventricular end-diastolic maximum diameter,dLVmax)之比(d RVmax/dLVmax),右室舒张末容积(right ventricular end diastolic volume,RVEDV),右室收缩末容积(right ventricular end systolic volume,RVESV),进而计算右室射血分数(right ventricular ejection fraction,RVEF);每只大鼠均行右心导管术获取右室收缩压(right ventricular systolic pressure,RVSP)。采用SPSS 24.0统计软件,应用独立样本t检验及ANOVA分析比较不同时间点上述各参数的差异,采用Pearson相关性分析评价各参数与RVSP的相关性。结果:造模后第1周大鼠RVSP即较基线升高[(29.92±1.94)mmHg vs.(41.55±3.14)mmHg,P<0.01],后每周逐步升高,MPA、dRVmax/dLVmax及RVESV、RVEDV逐渐增大(P<0.01),RVEF在缺氧第2周显著降低(P<0.01)。MPA/AA、dRVmax/dLVmax、RVEF与RVSP具有较好的相关性(r分别为0.573、0.700、-0.760,P均<0.01)。结论:7.0T CMR可敏感地观察到PAH大鼠病程进展中肺动脉及右心形态功能的改变,为研究PAH的演变机制打下基础。 Objective:To observe the evolution of pulmonary artery diameters and cardiac functional changes in a rat model of pulmonary artery hypertension(PAH)using 7.0 T cardiac magnetic resonance(CMR). Methods:A rat model of PAH was established by hypoxia. A total of 36 rats were divided into 6 groups on average(baseline,hypoxia at 1 st,2 nd,3 rd,4 th,and 5 thweeks;n=6). CMR was performed every week by Bruker BioSpec 7.0 T. The diameters of the main pulmonary artery(MPA),right pulmonary artery(RPA),left pulmonary artery(LPA),right ventricular end-diastolic maximum diameter(dRVmax),left ventricular end-diastolic maximum diameter(dLVmax),right ventricular end-diastolic volume(RVEDV)and right ventricular end-systolic volume(RVESV)were measured on MR images;ratio of dRVmaxto dLVmax(dRVmax/dLVmax),ratio of the main pulmonary artery to the ascending aorta(MPA/AA,RPA/AA,and LPA/AA),right ventricular and left ventricular ejection fraction(RVEF)were calculated. Right ventricular systolic pressure(RVSP)was obtained by right heart catheterization after CMR imaging for each rat. Comparison of above-mentioned parameters at different time points was calculated by t test and ANOVA analysis(SPSS 24.0). Pearson correlation analysis was used to evaluate the correlation between above-mentioned parameters and RVSP. Results:The RVSP in model rats at the first week increased significantly compared with the baseline[(29.92 ± 1.94)mmHg vs.(41.55 ± 3.14)mmHg,P<0.01],and then gradually increased from the first week to the fifth(P < 0.01). MPA,dRVmax/dLVmax,RVESV,and RVEDV gradually increased(P<0.01). RVEF decreased significantly in the 2 nd week of modeling(P < 0.01). There were moderate correlations between the MPA/AA,dRVmax/dLVmax,RVEF and RVSP in model rats(r=0.573,r=0.700,r=-0.760,all P < 0.01). Conclusion:7.0 T CMR can sensitively observed changes in pulmonary artery diameter and right ventricular function during the progression of PAH rats,which lays a foundation for studying the evolutionary mechanism of PAH.
作者 袁小涵 徐怡 祝因苏 朱晓梅 俞敏 韩宏浩 Yuan Xiaohan;Xu Yi;Zhu Yinsu;Zhu Xiaomei;Yu Min;Han Honghao(Department of Radiology,the First Affiliated Hospital of NMU,Nanjing 210029,China;Department of Respiratory,the First Affiliated Hospital of NMU,Nanjing 210029,China)
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2019年第1期131-135,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家自然科学基金(81601464,81701651)
关键词 CMR 肺动脉高压 右室功能 大鼠 cardiac magnetic resonance pulmonary artery hypertension right ventricular function rat
  • 相关文献

参考文献3

二级参考文献71

  • 1荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 2荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志,2007,46(3):254-261. 被引量:1790
  • 4吴秀明,李继红,李春梅.瘦素在慢性阻塞性肺疾病患者诱导痰中的变化及意义[J].中国现代医学杂志,2007,17(15):1897-1899. 被引量:14
  • 5Proceeding of 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol, 2004,43(2 Suppl S) : 1S-90S.
  • 6Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126( Suppl 1 ) : 1 S-92S.
  • 7Galie N, Torbicki A, Barst A, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 2004,25 ( 24 ) : 2243-2278.
  • 8Barst RJ, McGoon M, Torbicki A,et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2004,43( 12 Suppl S) :40S-47S.
  • 9Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2004,43 (12) :5S-12S.
  • 10Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol, 2004,43(12 Suppl S) :25S-32S.

共引文献275

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部